REVVITY, INC.
RVTY
Trailing 12 months YoY growth · margin
- Revenue
- —
- Gross profit
- —
- Operating income
- —
- Free cash flow
- —
About REVVITY, INC.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Market data
Share price
Daily close · USD
Historical closing prices; only dates with recorded USD source data are available.
Against the benchmark
Rebased to 100
Rebased adjusted prices on matching dates. This is not a total-return comparison.
Operating metrics
The measures behind the business.
No operating metrics are currently published for this company.
Revenue mix
What the company sells, and where.
Revenue by location
Q1 26 · USD
Revenue around the world
Q1 26 · USD
Only separately named countries are coloured. Combined regions and other countries stay in the reported location breakdown.
Revenue by product
Quarterly · USD
Stacked periods reconcile exactly to reported revenue. Periods with missing or overlapping categories are left blank.
Revenue by segment
Quarterly · USD
Stacked periods reconcile exactly to reported revenue. Periods with missing or overlapping categories are left blank.
Revenue by product
FY 25 · USD
Reported categories are shown independently; no total or percentage is inferred.
Product growth
FY 24 to FY 25
Same fiscal period one year apart.
Revenue by segment
FY 25 · USD
Reported categories are shown independently; no total or percentage is inferred.
Segment growth
FY 24 to FY 25
Same fiscal period one year apart.
Revenue by location
FY 18 · USD
Revenue around the world
FY 18 · USD
Only separately named countries are coloured. Combined regions and other countries stay in the reported location breakdown.
Income statement
From revenue to profit.
Cash flow
Cash generated and cash spent.
Balance sheet
What the company owns and what it owes.
Financial statements
Every published field, with exact amounts and disclosure sources.
View full financial statements
Income Quarterly
| Metric | Q2 20262026-07-05 · USD | Q1 20262026-04-05 · USD |
|---|---|---|
| Total Revenue | 729,688,000USD | 711,118,000USD |
| Cost Of Revenue | 312,822,000USD | 323,463,000USD |
| Gross Profit | 416,866,000USD | 387,655,000USD |
| Research Development | 48,974,000USD | 57,887,000USD |
| Selling General Administrative | 278,576,000USD | 253,882,000USD |
| Total Operating Expenses | 327,550,000USD | 311,769,000USD |
| Operating Income | 89,316,000USD | 75,886,000USD |
| Total Other Income Expense Net | -25,785,000USD | -25,894,000USD |
| Interest Income | 5,259,000USD | 6,304,000USD |
| Interest Expense | 22,990,000USD | 24,718,000USD |
| Depreciation And Amortization | 102,068,000USD | — |
| Income Before Tax | 63,531,000USD | 49,992,000USD |
| Income Tax Expense | 10,050,000USD | 9,099,000USD |
| Discontinued Operations | -1,661,000USD | -175,000USD |
| Net Income | 51,820,000USD | 40,718,000USD |
| Source | DisclosureDeterministicFinal | DisclosureDeterministicFinal |
Balance sheet Quarterly
| Metric | Q2 20262026-07-05 · USD | Q1 20262026-04-05 · USD |
|---|---|---|
| Total Assets | 12,045,834,000USD | 11,996,590,000USD |
| Cash And Equivalents | 1,022,943,000USD | 860,320,000USD |
| Total Current Assets | 2,297,721,000USD | 2,128,317,000USD |
| Other Current Assets | 187,101,000USD | 189,112,000USD |
| Other Non Current Assets | 309,114,000USD | 322,099,000USD |
| Total Liabilities | 4,817,076,000USD | 4,813,851,000USD |
| Total Current Liabilities | 1,276,357,000USD | 1,238,644,000USD |
| Other Current Liabilities | 538,461,000USD | 493,134,000USD |
| Other Non Current Liabilities | 771,359,000USD | 800,859,000USD |
| Total Stockholder Equity | 7,228,758,000USD | 7,182,739,000USD |
| Total Equity Including Noncontrolling Interest | 7,228,758,000USD | 7,182,739,000USD |
| Short Long Term Debt | 572,156,000USD | 575,831,000USD |
| Long Term Debt | 2,633,094,000USD | 2,632,072,000USD |
| Deferred Revenue | 174,300,000USD | 171,700,000USD |
| Net Receivables | 709,175,000USD | 691,380,000USD |
| Inventory | 378,502,000USD | 387,505,000USD |
| Property Plant Equipment Net | 607,196,000USD | 628,890,000USD |
| Goodwill | 6,607,802,000USD | 6,610,750,000USD |
| Intangible Assets | 2,224,001,000USD | 2,306,534,000USD |
| Accounts Payable | 165,740,000USD | 169,679,000USD |
| Common Stock | 111,584,000USD | 111,629,000USD |
| Retained Earnings | 6,131,228,000USD | 6,087,222,000USD |
| Accumulated Other Comprehensive Income | -256,554,000USD | -253,556,000USD |
| Deferred Revenue Non Current | — | 66,800,000USD |
| Source | DisclosureDeterministicFinal | DisclosureDeterministicFinal |
Cash flow YTD
| Metric | Q2 20262026-07-05 · USD |
|---|---|
| Net Income | 92,538,000USD |
| Depreciation | 207,095,000USD |
| Stock Based Compensation | 19,446,000USD |
| Other Non Cash Items | 56,553,000USD |
| Unclassified Operating Cash Flow | -10,657,000USD |
| Change To Account Receivables | 43,916,000USD |
| Change To Inventory | -4,778,000USD |
| Change To Liabilities | -96,940,000USD |
| Change In Working Capital | -57,802,000USD |
| Operating Cash Flow | 307,173,000USD |
| Capital Expenditures | -30,848,000USD |
| Net Investments | 3,935,000USD |
| Other Investing Activities | 12,197,000USD |
| Unclassified Investing Cash Flow | -67,061,000USD |
| Investing Cash Flow | -81,777,000USD |
| Common Stock Issuance | 6,437,000USD |
| Net Common Stock Issuance | -102,488,000USD |
| Common Dividends Paid | -15,654,000USD |
| Other Financing Activities | -350,000USD |
| Unclassified Financing Cash Flow | 0USD |
| Financing Cash Flow | -112,055,000USD |
| Effect Of Forex Changes On Cash | -10,190,000USD |
| Change In Cash | 103,151,000USD |
| End Cash Flow | 1,024,181,000USD |
| Source | DisclosureDeterministicFinal |
Cash flow Quarterly
| Metric | Q1 20262026-04-05 · USD |
|---|---|
| Net Income | 40,718,000USD |
| Depreciation | 105,056,000USD |
| Stock Based Compensation | 8,715,000USD |
| Other Non Cash Items | 100,000USD |
| Unclassified Operating Cash Flow | -74,324,000USD |
| Change To Account Receivables | 61,547,000USD |
| Change To Inventory | -12,838,000USD |
| Change To Liabilities | -88,431,000USD |
| Change In Working Capital | 34,965,000USD |
| Operating Cash Flow | 115,230,000USD |
| Capital Expenditures | -19,775,000USD |
| Unclassified Investing Cash Flow | -58,497,000USD |
| Investing Cash Flow | -78,272,000USD |
| Net Common Stock Issuance | -86,496,000USD |
| Common Dividends Paid | -7,840,000USD |
| Unclassified Financing Cash Flow | 5,441,000USD |
| Financing Cash Flow | -88,895,000USD |
| Effect Of Forex Changes On Cash | -7,627,000USD |
| Change In Cash | -59,564,000USD |
| End Cash Flow | 861,466,000USD |
| Source | DisclosureDeterministicFinal |
Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. TTM requires four complete quarters. Missing values are not zero. Charts use rounded labels; financial statement tables retain exact amounts. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.